An emerging, recognizable facial phenotype in association with mutations in GLI-similar 3 ( GLIS3 )

Neonatal diabetes and hypothyroidism (NDH) syndrome was first described in 2003 in a consanguineous Saudi Arabian family where two out of four siblings were reported to have presented with proportionate IUGR, neonatal non-autoimmune diabetes mellitus, severe congenital hypothyroidism, cholestasis, congenital glaucoma, and polycystic kidneys. Liver disease progressed to hepatic fibrosis. The renal disease was characterised by enlarged kidneys and multiple small cysts with deficient cortico-medullary junction differentiation and normal kidney function. There was minor facial dysmorphism (depressed nasal bridge, large anterior fontanelle, long philtrum) reported but no facial photographs were published. Mutations in the transcription factor GLI-similar 3 (GLIS3) gene in the original family and two other families were subsequently reported in 2006. All affected individuals had neonatal diabetes, congenital hypothyroidism but glaucoma and liver and kidney involvement were less consistent features. Detailed descriptions of the facial dysmorphism have not been reported previously. In this report, we describe the common facial dysmorphism consisting of bilateral low-set ears, depressed nasal bridge with overhanging columella, elongated, upslanted palpebral fissures, persistent long philtrum with a thin vermilion border of the upper lip in a cohort of seven patients with GLIS3 mutations and report the emergence of a distinct, probably recognisable facial gestalt in this group which evolves with age

Supplementary Material for: Liver Disease and Other Comorbidities in Wolcott-Rallison Syndrome: Different Phenotype and Variable Associations in a Large Cohort

<p><b><i>Background:</i></b> Wolcott-Rallison syndrome (WRS) is caused by recessive <i>EIF2AK3</i> mutations and characterized by early-onset diabetes and skeletal dysplasia. Hepatic dysfunction has been reported in 60% of patients. <b><i>Aims:</i></b> To describe a cohort of WRS patients and discuss the pattern and management of their liver disease. <b><i>Methods:</i></b> Detailed phenotyping and direct sequencing of <i>EIF2AK3</i> gene were conducted in all patients. <b><i>Results:</i></b> Twenty-eight genetically confirmed patients (67% male; mean age 4.6 years) were identified. 17 different <i>EIF2AK3</i> mutations were detected, of which 2 were novel. The p.S991N mutation was associated with prolonged survival and p.I650T with delayed onset. All patients presented before 25 months with diabetes with variation in the frequency and severity of 10 other features. Liver disease, first manifested as non-autoimmune hepatitis, was the commonest extra-pancreatic feature identified in 85.7% (24/28). 22/24 had at least one episode of acute hepatic failure which was the cause of death in all deceased patients (13/28). One child was treated by liver transplantation and had no liver disease and better diabetes control for the following 6 years. <b><i>Conclusions:</i></b> Liver disease in WRS is more frequent than previously described and carries high mortality. The first experience with liver transplantation in WRS is encouraging.</p

Comprehensive screening of eight known causative genes in congenital hypothyroidism with gland-in-situ

Context: lower thyroid-stimulating hormone (TSH) screening cut-offs have doubled the ascertainment of congenital hypothyroidism (CH), particularly cases with a eutopically-located gland-in-situ (GIS). Although mutations in known dyshormonogenesis genes, or the thyroid-stimulating hormone receptor (TSHR) underlie some cases of CH with GIS, systematic screening of these eight genes has not previously been undertaken.Objective: to evaluate the contribution and molecular spectrum of mutations in eight known causative genes (TG, TPO, DUOX2, DUOXA2, SLC5A5, SLC26A4, IYD and TSHR) in CH cases with GIS.Patients, Design and Setting: we screened forty-nine CH cases with GIS from thirty-four ethnically diverse families, using next-generation sequencing. Pathogenicity of novel mutations was assessed in silico.Results: twenty-nine cases harbored likely disease-causing mutations. Monogenic defects (nineteen cases) most commonly involved TG (twelve), TPO (four), DUOX2 (two) and TSHR (one case). Ten cases harboured triallelic (digenic) mutations: TG and TPO (one); SLC26A4 and TPO (three) and DUOX2 and TG (six cases). Novel variants overall included fifteen TG, six TPO, and three DUOX2 mutations. Genetic basis was not ascertained in twenty patients, including fourteen familial cases.Conclusions: the aetiology ofCHwith GIS remains elusive, with only59%attributable to mutations in TSHR or known dyshormonogenesis-associated genes in a cohort enriched for familial cases. Biallelic TG or TPO mutations most commonly underlie severe CH. Triallelic defects are frequent, mandating future segregation studies in larger kindreds to assess their contribution to variable phenotype. A high proportion (~41%) of unsolved or ambiguous cases suggests novel genetic aetiologies that remain to be elucidated- See more at: http://press.endocrine.org/doi/10.1210/jc.2016-1879#sthash.8M832MqP.dpu

Comprehensive screening of eight known causative genes in congenital hypothyroidism with gland-in-situ

Context: lower thyroid-stimulating hormone (TSH) screening cut-offs have doubled the ascertainment of congenital hypothyroidism (CH), particularly cases with a eutopically-located gland-in-situ (GIS). Although mutations in known dyshormonogenesis genes, or the thyroid-stimulating hormone receptor (TSHR) underlie some cases of CH with GIS, systematic screening of these eight genes has not previously been undertaken.Objective: to evaluate the contribution and molecular spectrum of mutations in eight known causative genes (TG, TPO, DUOX2, DUOXA2, SLC5A5, SLC26A4, IYD and TSHR) in CH cases with GIS.Patients, Design and Setting: we screened forty-nine CH cases with GIS from thirty-four ethnically diverse families, using next-generation sequencing. Pathogenicity of novel mutations was assessed in silico.Results: twenty-nine cases harbored likely disease-causing mutations. Monogenic defects (nineteen cases) most commonly involved TG (twelve), TPO (four), DUOX2 (two) and TSHR (one case). Ten cases harboured triallelic (digenic) mutations: TG and TPO (one); SLC26A4 and TPO (three) and DUOX2 and TG (six cases). Novel variants overall included fifteen TG, six TPO, and three DUOX2 mutations. Genetic basis was not ascertained in twenty patients, including fourteen familial cases.Conclusions: the aetiology ofCHwith GIS remains elusive, with only59%attributable to mutations in TSHR or known dyshormonogenesis-associated genes in a cohort enriched for familial cases. Biallelic TG or TPO mutations most commonly underlie severe CH. Triallelic defects are frequent, mandating future segregation studies in larger kindreds to assess their contribution to variable phenotype. A high proportion (~41%) of unsolved or ambiguous cases suggests novel genetic aetiologies that remain to be elucidated- See more at: http://press.endocrine.org/doi/10.1210/jc.2016-1879#sthash.8M832MqP.dpu